Loading clinical trials...
Loading clinical trials...
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1(1)
The purpose of this study is to assess the clinical efficacy of the buprenorphine/naloxone combination tablet for alternate-day dosing and determine whether multiples of the daily dose are necessary to maintain an effective alternate day dosing regimen.
Alternate-day dosing with the 8mg buprenorphine-naloxone tablet is as safe and effective as daily dosing. Outcomes are improved when the total weekly dose provided during alternate-day dosing is equal to that given during daily dosing.
Age
18 - 64 years
Sex
ALL
Healthy Volunteers
No
University of Colorado Health Sciences Center
Denver, Colorado, United States
Start Date
April 1, 1997
Primary Completion Date
August 1, 1997
Completion Date
August 1, 1997
Last Updated
May 4, 2017
Heroin Dependence
DRUG
Lead Sponsor
University of Colorado, Denver
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05657106